DK3332789T3 - Cladribinkur til behandling af multipel sklerose - Google Patents
Cladribinkur til behandling af multipel sklerose Download PDFInfo
- Publication number
- DK3332789T3 DK3332789T3 DK18151634.5T DK18151634T DK3332789T3 DK 3332789 T3 DK3332789 T3 DK 3332789T3 DK 18151634 T DK18151634 T DK 18151634T DK 3332789 T3 DK3332789 T3 DK 3332789T3
- Authority
- DK
- Denmark
- Prior art keywords
- cladribincur
- treatment
- multiple sclerosis
- sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| EP14001970.4A EP2805723B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3332789T3 true DK3332789T3 (da) | 2022-07-11 |
Family
ID=36227798
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18151634.5T DK3332789T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
| DK14001970.4T DK2805723T3 (da) | 2004-12-22 | 2005-12-20 | Cladribin-regime til behandling af multipel sclerose |
| DK22166610.0T DK4070800T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14001970.4T DK2805723T3 (da) | 2004-12-22 | 2005-12-20 | Cladribin-regime til behandling af multipel sclerose |
| DK22166610.0T DK4070800T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (enExample) |
| EP (7) | EP2275110B1 (enExample) |
| JP (7) | JP5795456B2 (enExample) |
| KR (1) | KR20070091662A (enExample) |
| AR (1) | AR052830A1 (enExample) |
| AU (2) | AU2005318190B2 (enExample) |
| BR (1) | BRPI0517132B8 (enExample) |
| CA (2) | CA2588966C (enExample) |
| CY (3) | CY1112614T1 (enExample) |
| DK (3) | DK3332789T3 (enExample) |
| EA (1) | EA015799B1 (enExample) |
| ES (2) | ES2921858T3 (enExample) |
| FI (1) | FI4070800T3 (enExample) |
| FR (1) | FR18C1008I2 (enExample) |
| HR (1) | HRP20120228T1 (enExample) |
| HU (3) | HUE059133T2 (enExample) |
| IL (2) | IL183930A0 (enExample) |
| LT (3) | LT3332789T (enExample) |
| LU (1) | LUC00064I2 (enExample) |
| MX (1) | MX2007007610A (enExample) |
| NO (1) | NO20073813L (enExample) |
| PL (4) | PL2805723T3 (enExample) |
| SG (1) | SG160391A1 (enExample) |
| SI (3) | SI2805723T1 (enExample) |
| WO (1) | WO2006067141A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2805723T3 (pl) | 2004-12-22 | 2018-04-30 | Merck Serono Sa | Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego |
| MX2008014971A (es) * | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| AR113906A1 (es) * | 2017-11-24 | 2020-06-24 | Merck Patent Ges Mit Beschraenkter Haftung | Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple |
| IL301246A (en) | 2020-09-10 | 2023-05-01 | Merck Patent Gmbh | Treatment regimen with cladribine |
| GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| PL321431A1 (en) | 1994-12-22 | 1997-12-08 | Ortho Pharma Corp | Soluble 2-chloro-2'deoxyadenosine compositions |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| WO2004028462A2 (en) | 2002-09-25 | 2004-04-08 | Brigham Young University, Technology Transfer Office | Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| BRPI0407781A (pt) * | 2003-02-25 | 2006-02-14 | Applied Research Systems | aplicação combinada de ribavirina e interferon beta em doenças desmielinizantes |
| WO2004087101A2 (en) | 2003-03-28 | 2004-10-14 | Ivax Corporation | Oral formulations of cladribine |
| ES2584183T3 (es) | 2003-03-28 | 2016-09-26 | Ares Trading S.A. | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
| PL2805723T3 (pl) | 2004-12-22 | 2018-04-30 | Merck Serono Sa | Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego |
| MX2008014971A (es) * | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
-
2005
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Revoked
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en not_active Withdrawn
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en not_active Expired - Lifetime
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1828164T3 (da) | Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider | |
| DK1778668T3 (da) | Fremgangsmåde til fremstilling af dihydropteridion | |
| DK1701941T3 (da) | Forbindelser til behandling af sygdomme med celleproliferation | |
| DK1720571T3 (da) | Fremgangsmåde til behandling af hæmolytisk sygdom | |
| DK2653873T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
| DK2308507T3 (da) | Fremgangsmåder til behandling af præeklampsi | |
| DK1755661T3 (da) | Gelsolin til anvendelse til behandling af infektioner | |
| DK1720866T3 (da) | Fremgangsmåde | |
| DK1928438T3 (da) | Anvendelse af ibudilast til behandling af stofafhængighed | |
| DK1893586T3 (da) | Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler | |
| DK1567152T3 (da) | Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DK1708992T3 (da) | Sulfonamidderivater til behandling af sygdomme | |
| DK1801108T3 (da) | Morpholinforbindelser til behandling af inflammationer. | |
| DK1763520T3 (da) | Anvendelse af trisubstituerede benzopyranoner | |
| DK4070800T3 (da) | Cladribinkur til behandling af multipel sklerose | |
| DK1687297T3 (da) | Triazindimerer til behandling af autoimmunsygdomme | |
| DK1709082T3 (da) | Sammensætning til behandling af patologi knyttet til MSRV/HERV-W | |
| DK1541137T3 (da) | Transdermalt delivery system af gestoden | |
| DK1789529T3 (da) | Fremgangsmåde til forbedring af konserveringen af lactococcus | |
| DK1831223T3 (da) | Fremgangsmåde til fremstilling af L-biopterin | |
| DE602005005896D1 (de) | Bogenfalzeinrichtung | |
| DK1814555T3 (da) | S-mirtazapin til behandling af hedeture | |
| DK1812002T3 (da) | Behandling af mastitis | |
| DK1692137T3 (da) | Fremgangsmåde til fremstilling af tubulinininhibitorer |